Concepedia

Robert M. D. Davies

RM

3

Publications

352

Citations

3

H-Index

2007

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

Robert M. D. Davies is an author at AstraZeneca (United Kingdom) specializing in natural sciences, bioorganic chemistry, and drug discovery.

Top concepts

Publications per year

2007–2017

3

Publications

3

(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18

Woods Wannamaker, Robert M. D. Davies, Mark Namchuk et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 309 citations

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

William McCoull, Andrew Bailey, Peter Barton et al. · Journal of Medicinal Chemistry · 2017 · 33 citations · Full text

, , +12

Synthesis of Novel Amino Acids Containing Cubane

Joanna Wlochal, Robert M. D. Davies, Jonathan W. Burton · Synlett · 2015 · 10 citations

, , +9

Rows per page

1–3 of 3